Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a411f4da2d9e4bc2

Jump to content

HGC019

From Wikipedia, the free encyclopedia

HGC019
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Other namesHGCO19, Gemcovac, GEMCOVAC-19
Routes of
administration		Intramuscular
ATC code
  • None

HGC019 is a mRNA and Self-amplifying mRNA (saRNA) based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.[1]

Clinical trials

[edit]

The phase-I trials began in February 2021 after receiving permission from Drugs Controller General of India (DGCI),[2][3] to evaluate the safety and immunogenicity of the vaccine candidate in about 120 participants consisting of age group (18–70) years.[4]

The phase-II trials is planned to conduct with 500 participants from the age group (18–75) years.[4] On 24 August 2021, the Drugs Controller General of India gave a go for phase II/III trials after it was found to be safe, tolerable, and immunogenic in the phase I trial results.[5][6][7]

Economics

[edit]

The company has received a funding of ₹250 crore (around US$33.5 million) from Government of India based on the clinical trials progress.[8]

References

[edit]
  1. ↑ "mRNA Vaccines – HGC019". Gennova Biopharmaceuticals Limited. Archived from the original on 3 May 2021. Retrieved 13 January 2021.
  2. ↑ "Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials" (Press release). Press Information Bureau. Retrieved 13 January 2021.
  3. ↑ Raghavan P (15 December 2020). "Pune-based Gennova to begin human trials of its Covid vaccine 'soon'". The Indian Express.
  4. 1 2 "Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants". ctri.nic.in. Clinical Trials Registry India. Retrieved 5 June 2021.
  5. ↑ "DBT-BIRAC supported Nation's first mRNA-based vaccine found to be safe gets a nod from the Drugs Controller General of India DCG(I) to move into Phase II/III trial" (Press release). Press Information Bureau. Retrieved 25 August 2021.
  6. ↑ "India's first mRNA vaccine found to be safe, given nod for Phase II/III trial". mint. 24 August 2021.
  7. ↑ Singh S (24 August 2021). "India approves further trials for first homegrown mRNA COVID-19 shot". Reuters.
  8. ↑ Geeta N (26 May 2021). "Trials of India's first mRNA Covid vaccine by Gennova on track". The Financial Express.
[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=HGC019&oldid=1321623291"